Articles Related to antagonist
A monoclonal antibody (Mab) designated as GHR106 was generated against the extracellular domain (N1-29 synthetic peptide) of human gonadotropin releasing hormone (GnRH) receptor. It is a first-in-class GnRH analog and can serve as a drug candidate for potential applications in the treatment of human cancers and/or fertility regulations.
Pharmacy Compounding Quality Control and Pharmaceutical Development Strategies for Seventeen alpha Hydroxyprogesterone Caproate in Prevention of Preterm Delivery
Seventeen alpha hydroxyprogesterone caproate (17-OHPC) is the only FDA-approved drug labeled for prevention of preterm delivery. This drug is also available as a compounded product from licensed compounding pharmacies. This article reviews the FDA approval history and pharmacy compounding quality control data of 17-OHPC, as well as briefly discusses possible future pharmaceutical development strategies for 17-OHPC.
Reduction of Bitterness and Enhancing Palatability of Cetirizine Oral Liquid Dosage Forms by Cyclodextrins
The aim of this manuscript is to study cyclodextrins (CDs) as a potential excipient to suppress bitterness and enhance palatability of pediatric liquid preparations for Cetirizine, an extremely bitter drug. Natural α, β and γ CDs; and β CD derivatives such as hydroxyl propyl (HP), randomly methylated (RM) and sulfobutyl ether (SBE) β-CDs were screened in different molar ratios of 1:1, 1:2 and 1:3 for their inhibition of the extremely bitter taste of Cetirizine using the human gustatory sensation test.
At the beginning of 2009, Dianne Wysowski of the US Food and Drug Administration summarized 23 reports of esophageal1 cancer following alendronate use. Wysowski also noted that there had been 31 cases following alendronate use in Europe and Japan and ten cases in which other bisphosphonates had been reported as concomitant or suspect treatment.